2021 Fiscal Year Final Research Report
Development of fail-safe system for human iPSC-derived tumor by CAR-T cell therapyCAR-T cell therapy
| Project/Area Number |
20K21608
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 53:Organ-based internal medicine and related fields
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
Fukuda Keiichi 慶應義塾大学, 医学部(信濃町), 教授 (20199227)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
岡田 麻里奈 慶應義塾大学, 医学部(信濃町), 助教 (00594582)
谷口 智憲 慶應義塾大学, 医学部(信濃町), 講師 (40424163)
遠山 周吾 慶應義塾大学, 医学部(信濃町), 講師 (90528192)
|
|---|
| Project Period (FY) |
2020-07-30 – 2022-03-31
|
| Keywords | CART細胞療法 / 未分化細胞除去法 / iPS細胞 / 心筋細胞移植 |
|---|
| Outline of Final Research Achievements |
We completed the production of monoclonal antibody against GPC3, the production of chimeric antigen receptor (CAR) by gene modification, and the production of CAR-T against GPC3, and confirmed the strong cytotoxic effect on GPC3-expressing cells. Furthermore, we confirmed that it did not act on differentiated cells from iPS cells, but only on residual iPS cells. In animal experiments with mice, we elucidated that CAR-T cells administration suppressed teratoma formation when iPS cells were transplanted.
|
| Free Research Field |
循環器内科
|
| Academic Significance and Societal Importance of the Research Achievements |
申請者らはこれまでに、ヒトiPS細胞に特異的に発現し、分化心筋細胞には発現していない細胞膜表面抗原としてGPC3を同定し、これを標的抗原とするGPC3特異的細胞傷害性T細胞 (CTL) 療法を開発してきた(BBRC 2019)。また、ヒトiPS細胞由来の奇形腫においてGPC3が高発現していることを初めて見出し、GPC3を標的としたCAR-T細胞療法の免疫学的アプローチにより再生医療における全ての領域で応用可能な非侵襲的腫瘍除去法の確立を可能とした。
|
